Nishant Shah

Journal Article Current Cardiovascular Risk Reports · December 1, 2025 Purpose of Review: To critically review the literature and summarize the available evidence to better understand the association of Lipoprotein(a) [Lp(a)] and calcific valve disease. Recent Findings: Serum Lp(a) is a causal and independent biomarker associ ... Full text Cite

Shared Decision-Making for Restoring Trust in the Management of Atherosclerotic Cardiovascular Disease in the Post-pandemic Era.

Journal Article Adv Ther · May 22, 2025 Real-world data indicate that the management of low-density lipoprotein cholesterol (LDL-C) is suboptimal in clinical practice and that many patients fail to reach guideline-recommended LDL-C goals. This may be due in part to physician inertia with regard ... Full text Link to item Cite

Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer.

Journal Article Cardiooncology · March 29, 2025 Over 1 million cases of prostate cancer are reported every year, and it is the second most common cancer in men. Androgen deprivation therapy (ADT) is a hallmark treatment for prostate cancer but is associated with the development or exacerbation of cardio ... Full text Link to item Cite

View All Publications

Recent Grants

MK-0616

Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC. · 2024 - 2030

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) OCEAN(a)-Outcomes- Olpasiran trials

Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2028

V-INCLUSION

Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2024 - 2027

View All Grants

Education, Training & Certifications

Wake Forest University, School of Medicine · 2013 M.D.